****

**Figure S1: Constitutive activation of AKT signaling enhances the resistance of saracatinib in HN8 cells.** (**A**) The effect of AKT-CA transfection on AKT activation determined by Western blotting. (**B**) The effect of AKT-CA transfection on cell viability in the presence or absence of saracatinib determined by CellTiter-Glo® Luminescent Cell Viability Kit on day 3 after treatment. \**p*<0.05; \*\**p*<0.01.